This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Review

. 2002 Jul;2(7):489-501.

doi: 10.1038/nrc839.

The phosphatidylinositol 3-Kinase AKT pathway in human cancer

Igor Vivanco¹, Charles L Sawyers

Affiliations

Affiliation

¹ Department of Medicine and Molecular Biology Institute, UCLA School of Medicine, 11-935 Factor Building, 10833 LeConte Avenue, Los Angeles, California 90095, USA.

PMID: 12094235
DOI: 10.1038/nrc839

Review

The phosphatidylinositol 3-Kinase AKT pathway in human cancer

Igor Vivanco et al. Nat Rev Cancer. 2002 Jul.

. 2002 Jul;2(7):489-501.

doi: 10.1038/nrc839.

Authors

Igor Vivanco¹, Charles L Sawyers

Affiliation

¹ Department of Medicine and Molecular Biology Institute, UCLA School of Medicine, 11-935 Factor Building, 10833 LeConte Avenue, Los Angeles, California 90095, USA.

PMID: 12094235
DOI: 10.1038/nrc839

No abstract available

PubMed Disclaimer

Similar articles

The phosphoinositide 3-kinase pathway.
Cantley LC. Cantley LC. Science. 2002 May 31;296(5573):1655-7. doi: 10.1126/science.296.5573.1655. Science. 2002. PMID: 12040186 Review.
Targeting the PI3K-Akt pathway in human cancer: rationale and promise.
Luo J, Manning BD, Cantley LC. Luo J, et al. Cancer Cell. 2003 Oct;4(4):257-62. doi: 10.1016/s1535-6108(03)00248-4. Cancer Cell. 2003. PMID: 14585353 Review. No abstract available.
Introduction: multifaceted roles of lipids and their catabolites in immune cell signaling.
Ott VL, Cambier JC. Ott VL, et al. Semin Immunol. 2002 Feb;14(1):1-6. doi: 10.1006/smim.2001.0336. Semin Immunol. 2002. PMID: 11884225 Review. No abstract available.
Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance.
Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S, Nakshatri H. Campbell RA, et al. J Biol Chem. 2001 Mar 30;276(13):9817-24. doi: 10.1074/jbc.M010840200. Epub 2001 Jan 3. J Biol Chem. 2001. PMID: 11139588
The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase.
Franke TF, Yang SI, Chan TO, Datta K, Kazlauskas A, Morrison DK, Kaplan DR, Tsichlis PN. Franke TF, et al. Cell. 1995 Jun 2;81(5):727-36. doi: 10.1016/0092-8674(95)90534-0. Cell. 1995. PMID: 7774014

See all similar articles

Cited by

MicroRNA-126 is down-regulated in human esophageal squamous cell carcinoma and inhibits the proliferation and migration in EC109 cell via PI3K/AKT signaling pathway.
Nie ZC, Weng WH, Shang YS, Long Y, Li J, Xu YT, Li Z. Nie ZC, et al. Int J Clin Exp Pathol. 2015 May 1;8(5):4745-54. eCollection 2015. Int J Clin Exp Pathol. 2015. PMID: 26191164 Free PMC article.
β-Cryptoxanthin Reduced Lung Tumor Multiplicity and Inhibited Lung Cancer Cell Motility by Downregulating Nicotinic Acetylcholine Receptor α7 Signaling.
Iskandar AR, Miao B, Li X, Hu KQ, Liu C, Wang XD. Iskandar AR, et al. Cancer Prev Res (Phila). 2016 Nov;9(11):875-886. doi: 10.1158/1940-6207.CAPR-16-0161. Epub 2016 Sep 13. Cancer Prev Res (Phila). 2016. PMID: 27623933 Free PMC article.
MicroRNA-93 activates c-Met/PI3K/Akt pathway activity in hepatocellular carcinoma by directly inhibiting PTEN and CDKN1A.
Ohta K, Hoshino H, Wang J, Ono S, Iida Y, Hata K, Huang SK, Colquhoun S, Hoon DS. Ohta K, et al. Oncotarget. 2015 Feb 20;6(5):3211-24. doi: 10.18632/oncotarget.3085. Oncotarget. 2015. PMID: 25633810 Free PMC article.
Drug repositioning for gynecologic tumors: a new therapeutic strategy for cancer.
Banno K, Iida M, Yanokura M, Irie H, Masuda K, Kobayashi Y, Tominaga E, Aoki D. Banno K, et al. ScientificWorldJournal. 2015;2015:341362. doi: 10.1155/2015/341362. Epub 2015 Feb 3. ScientificWorldJournal. 2015. PMID: 25734181 Free PMC article. Review.
Safety and tolerability of AZD8055 in Japanese patients with advanced solid tumors; a dose-finding phase I study.
Asahina H, Nokihara H, Yamamoto N, Yamada Y, Tamura Y, Honda K, Seki Y, Tanabe Y, Shimada H, Shi X, Tamura T. Asahina H, et al. Invest New Drugs. 2013 Jun;31(3):677-84. doi: 10.1007/s10637-012-9860-4. Epub 2012 Jul 28. Invest New Drugs. 2013. PMID: 22843211 Clinical Trial.

See all "Cited by" articles

Publication types

Actions
Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
Other Literature Sources
- The Lens - Patent Citations Database
Molecular Biology Databases
- GlyGen glycoinformatics resource
Miscellaneous
- NCI CPTAC Assay Portal